OBJECTIVE: To systematically evaluate the the safety and efficacy of budesonide combined with pulmonary surfactant（PS） in the treatment of neonatal respiratory distress syndrome（NRDS）. METHODS: CNKI

Wanfang Data

CBM

VIP database

PubMed

Embase and the Cochrance Library were retrieved to collect the randomized controlled trial of budesonide combined with PS in the treatment of NRDS（the control group was treated with PS alone

while the study group received budesonide combined with PS）. Literature that met the inclusion criteria were extracted and quality evaluation was carried out. Meta-analysis was performed by using RevMan 5.3 software. RESULTS: A total of 15 related studies were enrolled

including 1 317 children. Meta-analysis results showed that the clinical effective rate（RR=1.25

95%CI=1.16-1.36） in the study group was significantly higher than that in the control group

and the increase in partial pressure of oxygen（MD=8.02

95%CI=6.25-9.79）

decrease in partial pressure of carbon dioxide（MD=-5.72

95%CI=-6.70--4.75） and decrease in oxygen index（MD=-2.61

95%CI=-2.97--2.25） were significantly better than those in the control group

ventilator ventilation time（MD=-1.50

95%CI=-1.79--1.22） was significantly shorter than the control group

PS re-use rate（RR=0.31

95%CI=0.16-0.60）

incidence of moderate to severe bronchopulmonary dysplasia（RR=0.30

95%CI=0.22-0.43） were significantly lower than those of the control group

and the above differences were statistically significant（P<0.05）. No adverse drug reactions were observed. Egger’s test showed no significant publication bias. CONCLUSIONS: Budesonide combined with PS can improve the short-term clinical efficacy through improving the respiratory distress of NRDS

shortening the respiratory ventilation time

decreasing the PS re-use rate and incidence of moderate to severe bronchopulmonary dysplasia.